Product Code: RP-ID-10326778 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10326778
Market Overview:
Global Antihypertensive Drugs Market Size study, by Therapeutic Class (Diuretics, Angiotensin-Converting Enzyme (ACE) Inhibitors, Calcium Channel Blockers, Vasodilators, Beta-adrenergic Blockers, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Regional Forecasts 2020-2027
Global Antihypertensive Drugs Market is valued at approximately USD 23.2 million in 2019 and is anticipated to grow with a healthy growth rate of more than 3.1% over the forecast period 2020-2027. Antihypertensive drug is the class of drug used in the treatment of hypertension (high blood pressure). Hypertension is one of the leading causes of heart complications, such as heart failure, heart attack, and dementia. Thus, the treatment of hypertension must be integrated into an overall program to manage factors that intensify the risk of cardiovascular events (such as stroke and myocardial infarction). Therefore, there are a variety of antihypertensive drugs has been developed for treating hypertension. Some of the major antihypertensive drugs are thiazide diuretics, beta-adrenoceptor antagonists (beta-blockers), dihydropyridine calcium-channel blockers, and many more. These drugs can reduce the blood pressure rates and can prevent the health complications associated with high blood pressure. Therefore, these factors are anticipated to accelerate the market growth around the world. Moreover, the rise in cases of hypertension across the globe, followed by the growing elderly population are few other factors responsible for the market growth over the forecast period. According to the World Health Organization (WHO), around 1.3 billion people have hypertension around the world. Also, the possibility of its prevalence increases with age. As per the Framingham Heart Study, hypertension eventually developed in over 90% of participants with normal blood pressure at 55 years of age. By age 60 years of age, nearly 60% of the population has hypertension, by 70 years, about 65% of men and 75% of women have hypertension. This, in turn, is likely to accelerate the demand for drugs all over the world. Recently, the COVID-19 is widely spread throughout the world, thus various regional governments are mandating the use of drugs among the patients to prevent or mitigate the risk of respiratory-related problems. This is likely to strengthen the usage for antihypertensive drugs that encourage the manufacturers to produce them thereby, the market would grow at a significant rate in the forthcoming years. However, side-effects related to the use of drugs is one of the major factors impeding the market growth over the forecast period of 2020-2027.
The regional analysis of the global Antihypertensive Drugs market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to rise in prevalence of hypertension, along with the significant initiatives opt by the market players in the region. Whereas, Asia-Pacific is anticipated to exhibit the highest growth rate / CAGR over the forecast period 2020-2027. Factors such as rising geriatric population and increasing incidences of heart attack and failures among people would create lucrative growth prospects for the Antihypertensive Drugs market across the Asia-Pacific region.
Major market player included in this report are:
Boehringer Ingelheim International GmbH
Merck & Co., KGaA
Johnson and Johnson
Bayer AG
Pfizer, Inc.
Takeda Pharmaceutical Co. Ltd.
AstraZeneca plc
Daiichi Sankyo Company, Ltd.
Sanofi S.A.
Novartis International AG
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Therapeutic Class:
Diuretics
Angiotensin-Converting Enzyme (ACE) Inhibitors
Calcium Channel Blockers
Vasodilators
Beta-adrenergic Blockers
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027
Target Audience of the Global Antihypertensive Drugs Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
Boehringer Ingelheim International GmbH
Merck & Co., KGaA
Johnson and Johnson
Bayer AG
Pfizer, Inc.
Takeda Pharmaceutical Co. Ltd.
AstraZeneca plc
Daiichi Sankyo Company, Ltd.
Sanofi S.A.
Novartis International AG
Related Reports
Proof of Quality & Reliability
